TheraRadar
← Back
Data updated: May 24, 2026

ACROTECH BIOPHARMA

Specialty
OncologyDermatology Execution: Good

ACROTECH BIOPHARMA is a specialty pharmaceutical company focused on Oncology, Dermatology. Key products include BELEODAQ.

2008
Since
6
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
4 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

BELEODAQ
Oncology

Peripheral T-Cell Lymphoma

HDAC Approved 2014
EVOMELA
Oncology

Multiple Myeloma

DNA Approved 2016
ADQUEY
Dermatology
Approved 2026

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

ADQUEY NDA
2026-02-12
difamilast
1 INDICATIONS & USAGE ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. ADQUEY is a phosphodiesterase 4 inhibitor indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. (1)

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 85%
3 drugs Phase 3: 1 Phase 2: 5 Phase 1: 12
Dermatology 15%
0 drugs Phase 3: 2

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

3
Phase 3
5
Phase 2
12
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • BELEODAQ leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/3 completed
  • • Speed: 36 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges